Teneligliptin in management of type 2 diabetes mellitus

References

• IDF IDF Diabetes Atlas 7th Edn Brussels, Belgium International Diabetes Federation 2015
   Google Scholar
• American Diabetes Association Strategies for improving care Diabetes Care 2016 39 suppl 1 S6 S12 26696683
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Foundations of care and comprehensive medical evaluation Diabetes Care 2016 39 suppl 1 S23 S35 26696676
   PubMed Web of Science ®Google Scholar
• Majumdar SK Inzucchi SE Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine 2013 44 1 47 58 23354728
   PubMed Web of Science ®Google Scholar
• Kishimoto M Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes Diabetes Metab Syndr Obes 2013 6 187 195 23671395
   PubMedGoogle Scholar
• Scott LJ Teneligliptin: a review in type 2 diabetes Clin Drug Investig 2015 35 11 765 772
   PubMed Web of Science ®Google Scholar
• https://aiocdawacs.com [homepage on the Internet] Teneligliptin Data. Feb MAT 2016. Data Source from AIOCD-AWACS Available from: https://aiocdawacs.com/Default.aspx Accessed June 8, 2016
   Google Scholar
• Seuring T Archangelidi O Suhrcke M The economic costs of type 2 diabetes: a global systematic review Pharmacoeconomics 2015 33 8 811 831 25787932
   PubMed Web of Science ®Google Scholar
• Handelsman Y Bloomgarden ZT Grunberger G American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015 Endocr Pract 2015 21 suppl 1 1 87 25869408
   PubMed Web of Science ®Google Scholar
• Stratton IM Adler AI Neil HA Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000 321 405 412 10938048
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB American Diabetes Association (ADA) European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 6 1364 1379 22517736
   PubMed Web of Science ®Google Scholar
• American Diabetes Association Approaches to glycemic treatment Diabetes Care 2016 39 suppl 1 S52 S59 26696682
   PubMed Web of Science ®Google Scholar
• Dror Dicker DPP-4 inhibitors impact on glycemic control and cardiovascular risk factors Diabetes Care 2011 34 2 S276 S278 21525468
   PubMed Web of Science ®Google Scholar
• Chen XW He ZX Zhou ZW Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus Clin Exp Pharmacol Physiol 2015 42 10 999 1024 26173919
   PubMed Web of Science ®Google Scholar
• Kushwaha RN Haq W Katti SB Discovery of 17 gliptins in 17-years of research for the treatment of type 2 diabetes: a synthetic overview Chem Biol Interface 2014 4 3 137 162
   Google Scholar
• Nabeno M Akahoshi F Kishida H A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site Biochem Biophys Res Commun 2013 434 2 191 196 23501107
   PubMed Web of Science ®Google Scholar
• Yoshida T Akahoshi F Sakashita H Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Bioorg Med Chem 2012 20 19 5705 5719 22959556
   PubMed Web of Science ®Google Scholar
• Adis R & D Insight Teneligliptin Cham Springer International Publishing AG 2015
   Google Scholar
• Halabi A Maatouk H Siegler KE Faisst N Lufft V Klause N Pharmacokinetics of teneligliptin in subjects with renal impairment Clin Pharmacol Drug Dev 2013 2 3 246 254 27121786
   PubMed Web of Science ®Google Scholar
• Otsuki H Kosaka T Nakamura K Shimomura F Kuwahara Y Tsukamoto T Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes Int Urol Nephrol 2014 46 2 427 432 24014134
   PubMed Web of Science ®Google Scholar
• Tanaka K Okada Y Mori H Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study Diabetol Int 2016 1 7 Available from: http://link.springer.com/article/10.1007%2Fs13340-016-0258-y Accessed June 8, 2016
   Google Scholar
• Eto T Inoue S Kadowaki T Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial Diabetes Obes Metab 2012 14 11 1040 1046 22776014
   PubMed Web of Science ®Google Scholar
• Kadowaki T Kondo K Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus Diabetes Obes Metab 2013 15 9 810 818 23464664
   PubMed Web of Science ®Google Scholar
• Kim MK Rhee EJ Han KA Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial Diabetes Obes Metab 2015 17 3 309 312 25475929
   PubMed Web of Science ®Google Scholar
• Kadowaki T Kondo K Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension Diabetes Obes Metab 2014 16 5 418 425 24205974
   PubMed Web of Science ®Google Scholar
• Kadowaki T Kondo KJ Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus J Diabetes Investig 2013 4 6 576 584
   PubMed Web of Science ®Google Scholar
• Tanaka S Suzuki K Aoki C Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy Diabetes Technol Ther 2014 16 12 840 845 25144424
   PubMed Web of Science ®Google Scholar
• No authors listed Gliptins, exenatide, liraglutide: “intestinal obstruction” Prescrire Int 2016 25 167 17
   Google Scholar
• Huml RA Turner JR webpage on the Internet The Current Regulatory Landscape for Cardiac & Cardiovascular Safety Assessments: Part I Available from: http://www.quintiles.com/~/media/library/experts/the-current-regulatory-landscape-for-cardiac-and-cardiovascular-safety-assessments-part-i.pdf Accessed April 08, 2016
   Google Scholar
• Heller S Darpö B Mitchell MI Considerations for assessing the potential effects of antidiabetes drugs on cardiac ventricular repolarization: a report from the Cardiac Safety Research Consortium Am Heart J 2015 170 1 23 35 26093861
   PubMed Web of Science ®Google Scholar
• Fisman EZ Tenenbaum A Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes Cardiovasc Diabetol 2015 14 1 129 26415691
   PubMed Web of Science ®Google Scholar
• Hashikata T Yamaoka-Tojo M Kakizaki R Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes Heart Vessels Epub 2015 8 13
   Web of Science ®Google Scholar
• Morishita R Nakagami H Teneligliptin: expectations for its pleiotropic action Expert Opin Pharmacother 2015 16 3 417 426 25597385
   PubMed Web of Science ®Google Scholar